RepliCel Life Sciences Market cap
What is the Market cap of RepliCel Life Sciences?
The Market cap of RepliCel Life Sciences, Inc. is $2.64M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with market cap similar to RepliCel Life Sciences
- Tarku Resources has Market cap of $2.64M
- Onelife Capital Advisors has Market cap of $2.64M
- Goldcore Resources has Market cap of $2.64M
- E Lighting has Market cap of $2.64M
- ZoomAway Travel has Market cap of $2.64M
- Canterra Minerals has Market cap of $2.64M
- RepliCel Life Sciences has Market cap of $2.64M
- PHSC plc has Market cap of $2.65M
- Hapbee Technologies has Market cap of $2.65M
- Onlineformapro S.A has Market cap of $2.65M
- SSPDL has Market cap of $2.66M
- Appulse has Market cap of $2.66M
- Ormonde Mining plc has Market cap of $2.66M